Evolus enters $125M credit facility with Pharmakon Advisors; initial $75M draw

Evolus, Inc.

$75M drawn at close; up to $50M additional tranche available until Dec 31, 2022.
Facility matures in 6 years, interest-only for first 39 months; rate = 3-month LIBOR (1% floor) + 8.5%.
Proceeds for general corporate, working capital, and potential strategic transactions.
Company expects initial tranche to fund operations beyond cash flow breakeven, removing near-term equity dilution.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.